Merck【MRK】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

84.74

( 1.23% )

買値

売値

出来高

7,395,926

83.17 日の範囲 85.00

73.31 52 週間の範囲 129.93

時価総額

212.785B

前日終値

83.71

始値

83.79

時刻

84.74

最終取引時間

02:37:19

財務取引量

US$ 624,381,505

VWAP

84.4224

平均取引量 (3 か月)

16,252,806

発行済株式数

2,511,031,253

配当利回り

3.82%

PER

12.40

1 株当たり利益 (EPS)

6.82

歳入

64.17B

純利益

17.12B

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.merck.com

本社

West Trenton, New Jersey, USA

設立

Merck and Co Inc is listed in the Pharmaceutical Preparations sector of the ニューヨーク証券取引所 with ticker MRK. The last closing price for Merck was US$83.71. Over the last year, Merck shares have traded in a share price range of US$ 73.31 to US$ 129.93.

Merck currently has 2,511,031,253 shares in issue. The market capitalisation of Merck is US$210.20 billion. Merck has a price to earnings ratio (PE ratio) of 12.40.

全体の流れ

ブルリッシュ

ネットプレミアム

438k

Calls / Puts

195.83%

買い / 売り

122.58%

OTM / ITM

65.12%

Sweeps比率

0.00%

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Doravirine/islatravir would be the first FDA-approved two-drug regimen without an integrase inhibitor that demonstrated non-inferior efficacy and...

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary...

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV...

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of...

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of...

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 7, 2025 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: An estimated 20 million people are diagnosed annually with...

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.19	2.65293761357	82.55	85	80.15	13675507	81.9611617	CS
4	4.38	5.45047287208	80.36	85	77.1	18886876	80.27816115	CS
12	7.85	10.2093900377	76.89	85.83	73.31	16252806	79.2869747	CS
26	-14.52	-14.6282490429	99.26	101.79	73.31	16232783	84.82756776	CS
52	-40.94	-32.5747931254	125.68	129.93	73.31	13170464	94.20878572	CS
156	-8.14	-8.76399655469	92.88	134.63	73.31	9757660	102.60314616	CS
260	7.99	10.4104234528	76.75	134.63	70.89	10448746	92.60248813	CS

MRK - Frequently Asked Questions (FAQ)

What is the current Merck share price?

The current share price of Merck is US$ 84.74

How many Merck shares are in issue?

Merck has 2,511,031,253 shares in issue

What is the market cap of Merck?

The market capitalisation of Merck is USD 210.2B

What is the 1 year trading range for Merck share price?

Merck has traded in the range of US$ 73.31 to US$ 129.93 during the past year

What is the PE ratio of Merck?

The price to earnings ratio of Merck is 12.4

What is the cash to sales ratio of Merck?

The cash to sales ratio of Merck is 3.31

What is the reporting currency for Merck?

Merck reports financial results in USD

What is the latest annual turnover for Merck?

The latest annual turnover of Merck is USD 64.17B

What is the latest annual profit for Merck?

The latest annual profit of Merck is USD 17.12B

What is the registered address of Merck?

The registered address for Merck is 820 BEAR TAVERN ROAD, WEST TRENTON, NEW JERSEY, 08628 1021

What is the Merck website address?

The website address for Merck is www.merck.com

Which industry sector does Merck operate in?

Merck operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
BTCMBit Mining Limited	US$ 5.9708 (142.72%)	145.42M
SQNSSequans Communications SA	US$ 3.26 (57.49%)	20.67M
MPMP Materials Corp	US$ 44.00 (46.52%)	67.42M
KLGWK Kellogg Co	US$ 22.88 (30.74%)	31.93M
RFLRafael Holdings Inc	US$ 2.1494 (14.33%)	2.27M
MEIMethode Electronics Inc	US$ 7.7152 (-25.02%)	1.1M
WOLFWolfspeed Inc	US$ 1.6552 (-18.06%)	67.79M
LOCLLocal Bounti Corporation	US$ 2.76 (-9.21%)	27.22k
BEBloom Energy Corporation	US$ 26.11 (-9.06%)	13.5M
MODModine Manufacturing Co	US$ 91.805 (-6.97%)	2.5M
BTCMBit Mining Limited	US$ 5.9708 (142.72%)	145.42M
BBAIBigBear ai Holdings Inc	US$ 7.228 (-1.93%)	112.84M
NUNu Holdings Ltd	US$ 12.9399 (-5.13%)	72.52M
WOLFWolfspeed Inc	US$ 1.6552 (-18.06%)	67.79M
MPMP Materials Corp	US$ 44.00 (46.52%)	67.42M

銘柄コード

株価

出来高

BTCMBit Mining Limited

US$ 5.9708

(142.72%)

145.42M

BBAIBigBear ai Holdings Inc

US$ 7.228

(-1.93%)

112.84M

NUNu Holdings Ltd

US$ 12.9399

(-5.13%)

72.52M

WOLFWolfspeed Inc

US$ 1.6552

(-18.06%)

67.79M

MPMP Materials Corp

US$ 44.00

(46.52%)

67.42M

サインイン

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Merck and Co Inc (MRK) 銘柄情報

Merck and Co Inc (MRK)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Merck and Co Inc について

Merck (MRK) のオプションフロー概要

全体の流れ

ブルリッシュ

ネットプレミアム

438k

Calls / Puts

195.83%

買い / 売り

122.58%

OTM / ITM

65.12%

Sweeps比率

0.00%

MRK 最新ニュース

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

MRK - Frequently Asked Questions (FAQ)

ムーバー

MRK Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

サインイン

広告を削除する